Home
Clinical Trials
Stereotactic Body Radiation T...

Stereotactic Body Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Stage IIA-B Prostate Cancer

Last Updated: 2026-01-15

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

PHASE3

Total Enrollment

692 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-02-01

Study Completion Date

2027-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This randomized phase III trial studies how well stereotactic body radiation therapy works compared to intensity-modulated radiation therapy in treating patients with stage IIA-B prostate cancer. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method can kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. Stereotactic body radiation therapy may work better in treating patients with prostate cancer.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Radiation Therapy in Treating Patients With Stage II Prostate Cancer

NCT00331773

Prostate Cancer

COMPLETED PHASE3

Radiation Therapy in Treating Patients With Stage II Prostate Cancer

NCT00033631

Prostate Cancer

COMPLETED PHASE3

Interstitial Brachytherapy With or Without External-Beam Radiation Therapy in Treating Patients With Prostate Cancer

NCT00063882

Prostate Cancer

COMPLETED PHASE3

Radiation Therapy in Treating Patients With Stage II or Stage III Prostate Cancer

NCT00091390

Prostate Cancer

COMPLETED PHASE2

Radiation Therapy in Treating Patients With Stage II or Stage III Prostate Cancer

NCT00002602

Prostate Cancer

COMPLETED PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

PRIMARY OBJECTIVES:

I. To determine whether stereotactic body radiation therapy (SBRT) can be shown to be superior to hypofractionated intensity-modulated radiation therapy (IMRT) in terms of genitourinary (GU) and gastrointestinal (GI) toxicity by having fewer patients that experience a minimal important decline (MID) in urinary irritation/obstructive and bowel Health Related Quality of Life (HRQOL) as measured by Expanded Prostate Cancer Index Composite (EPIC)-26 at 24 months post completion of therapy.

II. To determine if SBRT (5 fractions of 7.25 Gy) is superior to hypofractionated IMRT (28 fractions of 2.5 Gy or 20 fractions of 3 Gy) as measured by disease free survival (DFS).

SECONDARY OBJECTIVES:

I. To determine whether SBRT can be shown to be superior to hypofractionated IMRT at 12 and 24 months post completion of therapy in terms of HRQOL by having fewer patients that experience a minimal important decline (MID) bowel (12 months only) sexual, hormonal, urinary irritation/obstructive (12 months only) and in urinary incontinence HRQOL as measured by EPIC-26.

II. To determine if SBRT (5 fractions of 7.25 Gy) is superior to hypofractionated IMRT (28 fractions of 2.5 Gy or 20 fractions of 3 Gy) as measured by biochemical failure, overall survival, local failure, prostate cancer specific survival, and distant metastases.

III. To determine the correspondence between the diagnostic magnetic resonance imaging (MRI) and biopsy.

IV. To determine if prostate imaging-reporting and data system (PIRADS)version (v)2.1 = 4/5 disease is prognostic for biochemical failure.

EXPLORATORY OBJECTIVES:

I. To determine whether a potentially more expensive therapy, SBRT, would be cost-effective than standard hypofractionated IMRT as measured by the European Quality of Life Five Dimension Five Level Scale Questionnaire (EQ-5D-5L).

II. To determine if disease characteristics captured on baseline and follow-up MRI can be used to predict which patients will respond to SBRT versus hypofractionated IMRT.

III. To validate autosegmentation tools for the prostate and tumors. IV. Collect specimens for future translational research analyses.

OUTLINE: Patients are randomized into 1 of 2 arms.

ARM I: Patients undergo IMRT once daily for 5 fractions per week for 20 or 28 fractions over less than 32 business days.

ARM II: Patients undergo SBRT at least every other day for 2-3 fractions per week over less than 17 business days.

After completion of study treatment, patients are followed up every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Stage II Prostate Adenocarcinoma AJCC v7

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Arm I (IMRT)

Patients undergo IMRT once daily for 5 fractions per week for 20 or 28 fractions over less than 32 business days.

Group Type ACTIVE_COMPARATOR

Intensity-Modulated Radiation Therapy

Intervention Type RADIATION

Undergo IMRT

Quality-of-Life Assessment

Intervention Type OTHER

Ancillary studies

Questionnaire Administration

Intervention Type OTHER

Ancillary studies

Arm II (SBRT)

Patients undergo SBRT at least every other day for 2-3 fractions per week over less than 17 business days.

Group Type EXPERIMENTAL

Quality-of-Life Assessment

Intervention Type OTHER

Ancillary studies

Questionnaire Administration

Intervention Type OTHER

Ancillary studies

Stereotactic Body Radiation Therapy

Intervention Type RADIATION

Undergo SBRT

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Intensity-Modulated Radiation Therapy

Undergo IMRT

Intervention Type RADIATION

Quality-of-Life Assessment

Ancillary studies

Intervention Type OTHER

Questionnaire Administration

Ancillary studies

Intervention Type OTHER

Stereotactic Body Radiation Therapy

Undergo SBRT

Intervention Type RADIATION

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

IMRT Intensity modulated radiation therapy (procedure) Intensity Modulated RT Intensity-Modulated Radiotherapy Radiation, Intensity-Modulated Radiotherapy Quality of Life Assessment SABR SBRT Stereotactic Ablative Body Radiation Therapy

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Previously untreated (no local therapy such as surgery, radiation cryotherapy, high-intensity focused ultrasound \[HIFU\], etc.) localized adenocarcinoma of the prostate with the following clinical findings:

* Clinical stage by digital rectal exam of either T1c or T2a/b (limited to one side of the gland); (American Joint Committee on Cancer \[AJCC\], version 7) or cT1a-c or 2a or 2b
* Stages T1a-T1b are eligible if patient underwent transurethral prostatic resection (TURP)
* The patient must meet one of the following 3 criteria: 1) Gleason score must be Gleason 7(3+4) with a PSA \< 20 ng/mL, or 2) Gleason 6 (3+3) with a PSA \> 10 ng/mL and \< 20 ng/mL which is considered intermediate risk and eligible for the study (AJCC, version 7), or 3) Group Grade 1 with a PSA \> 10 ng/mL and \< 20 ng/mL or 2 with a PSA \< 20 ng/mL

* If patient is receiving a 5-alpha reductase inhibitor at the time of enrollment, the baseline PSA value may be double the initial value and the medication should be discontinued but a washout period is not required; to be eligible, a PSA drawn while still on the medicine must be:

* \< 10 ng/mL if Gleason 7(3+4) (note this patient would be on stratification level 1 if PSA \< 5 ng/mL and stratification level 2 if less than 10 ng/mL)
* \> 5 ng/mL and less than 10 ng/mL for Gleason 6(3+3) (note this patient would be on stratification level 3)
* The prostate volume must be \< 70 cc as reported at time of biopsy or by separate measure with ultrasound or other imaging modalities including magnetic resonance imaging (MRI) or computed tomography (CT) scan
* Patients in active surveillance who elect to be treated are eligible if they meet protocol requirements
* Age \>= 18
* History and physical including a digital rectal exam 60 days prior to registration
* Eastern Cooperative Oncology Group (ECOG) performance status 0-1 60 days prior to registration
* MRI of the prostate and pelvis (per institutional standard of care \[SOC\] - should be compliant with PIRADSv2.1 guidelines) within 1 year prior to registration
* Bone scan as clinically indicated within 120 days prior to registration
* Charlson modified co-morbidity score =\< 4 for patients under 60 and =\< 5 for patients 60 and over 21 days prior to registration
* International prostate symptom score (IPSS) of \< 15 21 days prior to registration
* The patient must provide study-specific informed consent prior to study entry
* Willingness and ability to complete the Expanded Prostate Cancer Index Composite (EPIC-26) questionnaire
* Completion of all items of the EPIC-26 which will be data entered at registration 60 days prior to registration
* Only English, Spanish, and French-speaking patients are eligible to participate as these are the only languages EPIC-26 has been validated in

Exclusion Criteria

* Definitive clinical or radiologic evidence of metastatic disease; no nodal involvement or evidence of metastatic disease allowed as defined by screening of the pelvis
* Definitive T3 disease on MRI
* Prior or current invasive malignancy with current evidence of active disease within the past 2 years

* Exceptions: Non-melanomatous skin cancer, carcinoma in situ of the male breast, penis, oral cavity, or stage Ta of the bladder, or stage I completely resected melanoma
* Prior systemic chemotherapy for the study cancer; note that prior chemotherapy for a different cancer is allowable; must be off treatment for at least 3 years
* Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
* The use of hormonal therapy is not allowed; if the patient is on a 5-alpha reductase inhibitor, then they should be stopped prior to treatment once enrolled onto the study; no washout period is required for this study to participate
* Severe, active co-morbidity defined as follows:

* Human immunodeficiency virus (HIV) positive with CD4 count \< 200 cells/microliter; Note that patients who are HIV positive are eligible, provided they are under treatment with highly active antiretroviral therapy (HAART) and have a CD4 count \>= 200 cells/microliter within 30 days prior to registration; Note also that HIV testing is not required for eligibility for this protocol; this exclusion criterion is necessary because the treatments involved in this protocol may be significantly immunosuppressive
* Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects; note, however, that laboratory tests for liver function and coagulation parameters are not required for entry into this protocol; (patients on Coumadin or other blood thinning agents are eligible for this study)
* Contraindication to MRI

* Cardiac pacemaker or defibrillator
* Surgically implanted electrical devices such as spinal stimulation devices or intracranial stimulation devices, cochlear implants, the presence of metallic foreign bodies in the orbits, and incompatible old mechanical heart valves and aneurysm clips

Minimum Eligible Age

18 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Rodney J Ellis

Role: PRINCIPAL_INVESTIGATOR

NRG Oncology

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Mobile Infirmary Medical Center

Mobile, Alabama, United States

Site Status

Lewis and Faye Manderson Cancer Center

Tuscaloosa, Alabama, United States

Site Status

Arizona Center for Cancer Care - Gilbert

Gilbert, Arizona, United States

Site Status

Arizona Center for Cancer Care-Peoria

Peoria, Arizona, United States

Site Status

Arizona Center for Cancer Care - Scottsdale

Scottsdale, Arizona, United States

Site Status

Arizona Center for Cancer Care-Surprise

Surprise, Arizona, United States

Site Status

Arizona Oncology Associates-West Orange Grove

Tucson, Arizona, United States

Site Status

University of Arkansas for Medical Sciences

Little Rock, Arkansas, United States

Site Status

Kaiser Permanente-Anaheim

Anaheim, California, United States

Site Status

Alta Bates Summit Medical Center-Herrick Campus

Berkeley, California, United States

Site Status

Mercy Cancer Center - Carmichael

Carmichael, California, United States

Site Status

Mercy San Juan Medical Center

Carmichael, California, United States

Site Status

Kaiser Permanente Dublin

Dublin, California, United States

Site Status

Mercy Cancer Center - Elk Grove

Elk Grove, California, United States

Site Status

Fresno Cancer Center

Fresno, California, United States

Site Status

Marin General Hospital

Greenbrae, California, United States

Site Status

UC San Diego Moores Cancer Center

La Jolla, California, United States

Site Status

Kaiser Permanente Los Angeles Medical Center

Los Angeles, California, United States

Site Status

Los Angeles General Medical Center

Los Angeles, California, United States

Site Status

USC / Norris Comprehensive Cancer Center

Los Angeles, California, United States

Site Status

Memorial Medical Center

Modesto, California, United States

Site Status

Kaiser Permanente Oakland-Broadway

Oakland, California, United States

Site Status

Saint Joseph Hospital - Orange

Orange, California, United States

Site Status

Stanford Cancer Institute Palo Alto

Palo Alto, California, United States

Site Status

Kaiser Permanente-Rancho Cordova Cancer Center

Rancho Cordova, California, United States

Site Status

Mercy Cancer Center - Rocklin

Rocklin, California, United States

Site Status

Rohnert Park Cancer Center

Rohnert Park, California, United States

Site Status

The Permanente Medical Group-Roseville Radiation Oncology

Roseville, California, United States

Site Status

Mercy Cancer Center - Sacramento

Sacramento, California, United States

Site Status

Sutter Medical Center Sacramento

Sacramento, California, United States

Site Status

University of California Davis Comprehensive Cancer Center

Sacramento, California, United States

Site Status

Salinas Valley Memorial

Salinas, California, United States

Site Status

Stanford Cancer Center South Bay

San Jose, California, United States

Site Status

Kaiser Permanente Medical Center - Santa Clara

Santa Clara, California, United States

Site Status

Kaiser Permanente Cancer Treatment Center

South San Francisco, California, United States

Site Status

Gene Upshaw Memorial Tahoe Forest Cancer Center

Truckee, California, United States

Site Status

Woodland Memorial Hospital

Woodland, California, United States

Site Status

UCHealth University of Colorado Hospital

Aurora, Colorado, United States

Site Status

UCHealth Memorial Hospital Central

Colorado Springs, Colorado, United States

Site Status

Memorial Hospital North

Colorado Springs, Colorado, United States

Site Status

AdventHealth Porter

Denver, Colorado, United States

Site Status

Poudre Valley Hospital

Fort Collins, Colorado, United States

Site Status

Valley View Hospital Cancer Center

Glenwood Springs, Colorado, United States

Site Status

AdventHealth Littleton

Littleton, Colorado, United States

Site Status

AdventHealth Parker

Parker, Colorado, United States

Site Status

Smilow Cancer Hospital Care Center - Guilford

Guilford, Connecticut, United States

Site Status

Yale University

New Haven, Connecticut, United States

Site Status

Smilow Cancer Hospital Care Center-Trumbull

Trumbull, Connecticut, United States

Site Status

Smilow Cancer Hospital Care Center - Waterford

Waterford, Connecticut, United States

Site Status

Beebe South Coastal Health Campus

Millville, Delaware, United States

Site Status

Helen F Graham Cancer Center

Newark, Delaware, United States

Site Status

Christiana Care Health System-Christiana Hospital

Newark, Delaware, United States

Site Status

Beebe Health Campus

Rehoboth Beach, Delaware, United States

Site Status

John Fitzgerald Kennedy Medical Center

Atlantis, Florida, United States

Site Status

Mount Sinai Comprehensive Cancer Center at Aventura

Aventura, Florida, United States

Site Status

Broward Health North

Deerfield Beach, Florida, United States

Site Status

Broward Health Medical Center

Fort Lauderdale, Florida, United States

Site Status

GenesisCare USA - Key West

Key West, Florida, United States

Site Status

GenesisCare USA - Lakewood Ranch

Lakewood Rch, Florida, United States

Site Status

Mount Sinai Medical Center

Miami Beach, Florida, United States

Site Status